1. Home
  2. NTCT vs MNKD Comparison

NTCT vs MNKD Comparison

Compare NTCT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTCT
  • MNKD
  • Stock Information
  • Founded
  • NTCT 1984
  • MNKD 1991
  • Country
  • NTCT United States
  • MNKD United States
  • Employees
  • NTCT N/A
  • MNKD N/A
  • Industry
  • NTCT EDP Services
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • NTCT Technology
  • MNKD Health Care
  • Exchange
  • NTCT Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • NTCT 1.7B
  • MNKD 1.5B
  • IPO Year
  • NTCT 1999
  • MNKD 2004
  • Fundamental
  • Price
  • NTCT $23.70
  • MNKD $5.76
  • Analyst Decision
  • NTCT Hold
  • MNKD Buy
  • Analyst Count
  • NTCT 1
  • MNKD 6
  • Target Price
  • NTCT $25.00
  • MNKD $8.92
  • AVG Volume (30 Days)
  • NTCT 465.0K
  • MNKD 1.7M
  • Earning Date
  • NTCT 01-30-2025
  • MNKD 02-26-2025
  • Dividend Yield
  • NTCT N/A
  • MNKD N/A
  • EPS Growth
  • NTCT N/A
  • MNKD N/A
  • EPS
  • NTCT N/A
  • MNKD 0.08
  • Revenue
  • NTCT $821,135,000.00
  • MNKD $267,200,000.00
  • Revenue This Year
  • NTCT $0.09
  • MNKD $44.15
  • Revenue Next Year
  • NTCT $2.06
  • MNKD $19.65
  • P/E Ratio
  • NTCT N/A
  • MNKD $72.34
  • Revenue Growth
  • NTCT N/A
  • MNKD 51.35
  • 52 Week Low
  • NTCT $17.10
  • MNKD $3.47
  • 52 Week High
  • NTCT $27.89
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • NTCT 50.93
  • MNKD 48.03
  • Support Level
  • NTCT $23.49
  • MNKD $5.32
  • Resistance Level
  • NTCT $24.51
  • MNKD $5.65
  • Average True Range (ATR)
  • NTCT 0.74
  • MNKD 0.18
  • MACD
  • NTCT -0.10
  • MNKD 0.03
  • Stochastic Oscillator
  • NTCT 32.56
  • MNKD 81.48

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: